Buclin T - Search Results

1

[Antimicrobial agents and renal elimination: towards individual dosage adjustment?].

Willi-Robatel C, Senn L, Livio F, Zanetti G, Marchetti O, Buclin T. Willi-Robatel C, et al. Among authors: buclin t. Rev Med Suisse. 2012 Apr 25;8(338):894-900. Rev Med Suisse. 2012. PMID: 22611626 Review. French.

2

[Prognosis in brain stem infarction].

Exhenry C, Regli F, Bogousslavsky J, Buclin T, Van Melle G. Exhenry C, et al. Among authors: buclin t. Rev Med Suisse Romande. 1992 Jun;112(6):539-46. Rev Med Suisse Romande. 1992. PMID: 1631466 French.

3

[Importance and limitations of metabolic drug half-life].

Buclin T, Biollaz J. Buclin T, et al. Praxis (Bern 1994). 1997 Oct 22;86(43):1693-7. Praxis (Bern 1994). 1997. PMID: 9432694 Review. German.

4

Estimation of glomerular filtration rate by sinistrin clearance using various approaches.

Buclin T, Sechaud R, Bertschi AP, Decosterd LA, Belaz N, Appenzeller M, Burnier M, Biollaz J. Buclin T, et al. Ren Fail. 1998 Mar;20(2):267-76. doi: 10.3109/08860229809045111. Ren Fail. 1998. PMID: 9574452

5

Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A. Marzolini C, et al. Among authors: buclin t. Ther Drug Monit. 2001 Aug;23(4):394-8. doi: 10.1097/00007691-200108000-00012. Ther Drug Monit. 2001. PMID: 11477322

6

Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.

Csajka C, Buclin T, Fattinger K, Brunner HR, Biollaz J. Csajka C, et al. Among authors: buclin t. Clin Pharmacokinet. 2002;41(2):137-52. doi: 10.2165/00003088-200241020-00005. Clin Pharmacokinet. 2002. PMID: 11888333

7

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Csajka C, et al. Among authors: buclin t. Clin Pharmacol Ther. 2003 Jan;73(1):20-30. doi: 10.1067/mcp.2003.22. Clin Pharmacol Ther. 2003. PMID: 12545140

8

Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.

Robatel C, Decosterd LA, Biollaz J, Eckert P, Schaller MD, Buclin T. Robatel C, et al. Among authors: buclin t. J Clin Pharmacol. 2003 Dec;43(12):1329-40. doi: 10.1177/0091270003260286. J Clin Pharmacol. 2003. PMID: 14615469 Clinical Trial.

9

Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Telenti A, Biollaz J, Buclin T. Csajka C, et al. Among authors: buclin t. Antimicrob Agents Chemother. 2004 Sep;48(9):3226-32. doi: 10.1128/AAC.48.9.3226-3232.2004. Antimicrob Agents Chemother. 2004. PMID: 15328077 Free PMC article. Clinical Trial.

10

[Multiple diseases: should we treat them all?].

Biollaz J, Buclin T. Biollaz J, et al. Among authors: buclin t. Rev Med Suisse. 2005 Apr 6;1(14):941-7. Rev Med Suisse. 2005. PMID: 15898678 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results